These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries. Rajasingham R; Nalintya E; Israelski DM; Meya DB; Larson BA; Boulware DR Med Mycol; 2022 Feb; 60(2):. PubMed ID: 35026017 [TBL] [Abstract][Full Text] [Related]
9. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. Leenders AC; Reiss P; Portegies P; Clezy K; Hop WC; Hoy J; Borleffs JC; Allworth T; Kauffmann RH; Jones P; Kroon FP; Verbrugh HA; de Marie S AIDS; 1997 Oct; 11(12):1463-71. PubMed ID: 9342068 [TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B (Fungisome) for the treatment of cryptococcal meningitis in HIV/AIDS patients in India: a multicentric, randomized controlled trial. Jadhav MP; Bamba A; Shinde VM; Gogtay N; Kshirsagar NA; Bichile LS; Mathai D; Sharma A; Varma S; Digumarathi R J Postgrad Med; 2010; 56(2):71-5. PubMed ID: 20622383 [TBL] [Abstract][Full Text] [Related]
11. How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings? Harrison TS; Lawrence DS; Mwandumba HC; Boulware DR; Hosseinipour MC; Lortholary O; Meintjes G; Mosepele M; Jarvis JN Clin Infect Dis; 2023 Mar; 76(5):944-949. PubMed ID: 36166405 [TBL] [Abstract][Full Text] [Related]
12. The acceptability of the AMBITION-cm treatment regimen for HIV-associated cryptococcal meningitis: Findings from a qualitative methods study of participants and researchers in Botswana and Uganda. Lawrence DS; Ssali A; Moshashane N; Nabaggala G; Maphane L; Harrison TS; Meya DB; Jarvis JN; Seeley J PLoS Negl Trop Dis; 2022 Oct; 16(10):e0010825. PubMed ID: 36279300 [TBL] [Abstract][Full Text] [Related]
13. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Moen MD; Lyseng-Williamson KA; Scott LJ Drugs; 2009; 69(3):361-92. PubMed ID: 19275278 [TBL] [Abstract][Full Text] [Related]
14. Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. Jarvis JN; Leeme TB; Molefi M; Chofle AA; Bidwell G; Tsholo K; Tlhako N; Mawoko N; Patel RKK; Tenforde MW; Muthoga C; Bisson GP; Kidola J; Changalucha J; Lawrence D; Jaffar S; Hope W; Molloy SLF; Harrison TS Clin Infect Dis; 2019 Jan; 68(3):393-401. PubMed ID: 29945252 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa. Miot J; Leong T; Takuva S; Parrish A; Dawood H BMC Health Serv Res; 2021 Apr; 21(1):305. PubMed ID: 33823842 [TBL] [Abstract][Full Text] [Related]
16. Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa. Chen T; Mwenge L; Lakhi S; Chanda D; Mwaba P; Molloy SF; Gheorghe A; Griffiths UK; Heyderman RS; Kanyama C; Kouanfack C; Mfinanga S; Chan AK; Temfack E; Kivuyo S; Hosseinipour MC; Lortholary O; Loyse A; Jaffar S; Harrison TS; Niessen LW; Clin Infect Dis; 2019 Aug; 69(4):588-595. PubMed ID: 30863852 [TBL] [Abstract][Full Text] [Related]
17. Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis. Tenforde MW; Gertz AM; Lawrence DS; Wills NK; Guthrie BL; Farquhar C; Jarvis JN J Int AIDS Soc; 2020 Jan; 23(1):e25416. PubMed ID: 31957332 [TBL] [Abstract][Full Text] [Related]
18. Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study. Ahimbisibwe C; Kwizera R; Ndyetukira JF; Kugonza F; Sadiq A; Hullsiek KH; Williams DA; Rhein J; Boulware DR; Meya DB BMC Infect Dis; 2019 Jun; 19(1):558. PubMed ID: 31242860 [TBL] [Abstract][Full Text] [Related]
19. Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis. Merry M; Boulware DR Clin Infect Dis; 2016 Jun; 62(12):1564-8. PubMed ID: 27009249 [TBL] [Abstract][Full Text] [Related]
20. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Loyse A; Thangaraj H; Easterbrook P; Ford N; Roy M; Chiller T; Govender N; Harrison TS; Bicanic T Lancet Infect Dis; 2013 Jul; 13(7):629-37. PubMed ID: 23735626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]